Expanding HERG Screening Market Fueled By Increasing Prevalence Of Heart Disorders Is Supporting Development Across The HERG Screening Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The HERG Screening Market Increase Between 2026 And 2030?

The herg screening market has experienced rapid expansion in recent years. It is projected to expand from $1.84 billion in 2025 to $2.06 billion in 2026, registering a compound annual growth rate (CAGR) of 12.0%. Historically, this market’s expansion has been propelled by factors such as a rise in cardiac-related drug withdrawals, increased investment in preclinical safety studies, the growth of pharmaceutical R&D, the adoption of in-vitro ion channel assays, and heightened awareness of drug-induced arrhythmias.

The herg screening market is anticipated to experience significant expansion over the coming years. This market is projected to reach $3.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. This growth during the projection period stems from progress in AI-driven predictive toxicology, the incorporation of organ-on-chip technologies, the rise of biologics and personalized medicine, increased outsourcing to CDMOs, and the broadening of preclinical research in developing markets. Key trends anticipated for the forecast period encompass sophisticated cardiotoxicity modeling, the automation of high-throughput screening, the embedding of predictive analytics within preclinical safety assessments, the broadening of contract research services, and the development of miniaturized microfluidic assays.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

What Major Growth Factors Are Impacting The HERG Screening Market?

The HERG screening market is anticipated to expand due to an increase in patients suffering from heart disorders. These conditions, also known as cardiovascular diseases, encompass various ailments impacting the heart and blood vessels, potentially impairing heart function and leading to severe health issues. Unhealthy lifestyles, an aging demographic, genetic predispositions, diabetes, and metabolic syndrome contribute to these disorders. HERG screening plays a crucial role in identifying suitable drug candidates, averting serious cardiac incidents such as life-threatening cardiac arrhythmias, specifically torsade de pointes (TdP), and ultimately improving patient health. For example, the Australian Institute of Health and Welfare, an Australian government body, indicated in October 2025 that an estimated 57,100 adults aged 25 and above experienced acute coronary events in 2023, averaging approximately 156 incidents daily. Consequently, the growing prevalence of heart disorder patients is a key driver for the HERG screening market. The expanding aging population is projected to stimulate the growth of the HERG screening market moving ahead. An aging population signifies an increasing segment of older individuals within a community, largely attributed to longer life expectancies and decreased birth rates, with healthcare advancements playing a key role in extending lives. HERG screening is vital for this demographic, as it helps ascertain the safety of new medications for elderly patients by pinpointing compounds that might induce adverse cardiac effects. For instance, the US-based Population Reference Bureau stated in January 2024 that the number of Americans aged 65 and above is anticipated to climb from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Consequently, this age group’s share of the overall U.S. population is set to increase from 17% to 23% over this timeframe. Hence, the increasing aging population is a significant factor driving the HERG screening market.

How Is Segment Classification Applied In The HERG Screening Market?

The herg screening market covered in this report is segmented –

1) By Type: Gene KCNH2, Mutant KCNH2

2) By Ion Channel: Voltage-Gated, Ligand Gated

3) By Applications: Antiarrhythmic, Antipsychotic, Antibiotics, Other Applications

Subsegments:

1) By Gene KCNH2: Wild-Type KCNH2, Recombinant KCNH2

2) By Mutant KCNH2: Mutations: Missense Mutations, Nonsense Mutations, Frameshift Mutations

What Trends Are Driving Changes In The HERG Screening Market?

Leading companies in the HERG screening market are concentrating on advanced, innovative solutions, notably GLP-certified HERG screening services, to enhance cardiac safety evaluations throughout drug development. This specific service involves the good laboratory practice-certified screening of the human ether-à-go-go related gene (hERG) employing the standard whole-cell patch-clamp technique. Its purpose is to ensure adherence to regulatory guidelines such as ICH S7A and ICH S7B, which are critical for safety pharmacology studies during drug development. An example is Metrion Biosciences Ltd., a UK-based pharmaceutical company, which introduced its good laboratory practice (GLP)-certified hERG screening service in August 2023. This offering seeks to bolster Metrion’s support for small-molecule therapeutic development and complement its existing cardiac safety service portfolio. Furthermore, this service uses the conventional whole-cell patch-clamp technique to assess potential cardiac liabilities prior to human Phase 1 clinical trials, provides regulatory guidance for safety pharmacology studies in drug development, and offers clients high-quality biology services for ion channel targets.

Who Are The Prominent Players Across The HERG Screening Market?

Major companies operating in the herg screening market are Eurofins-Cerep SA, Aviva Biosciences Inc., AstraZeneca Public Limited Company, Merck KGaA, Charles River Laboratories Inc., Abcam Public Limited Company, Molecular Devices LLC, Caliper Life Sciences Inc., ChanTest Corporation, Creative Bioarray Inc., Cellular Dynamics International Inc., Nanion Technologies, Essen Bioscience, ACEA Biosciences Inc., Metrion Biosciences Inc., Aurora Biomed Inc., Aureus Sciences, RedShift BioAnalytics, Sophion Bioscience Inc., Fluxion Biosciences Inc.

Access The Complete HERG Screening Market Report:

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Which Region Holds The Largest Share In The HERG Screening Market?

North America was the largest region in the HERG screening market in 2025. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the herg screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access HERG Screening Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=14392&type=smp

Browse Through More Reports Similar to the Global HERG Screening Market 2026, By The Business Research Company

Herg Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/herg-screening-global-market-report

Cellular Health Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellular-health-screening-global-market-report

Carrier Screening Market Report 2026

https://www.thebusinessresearchcompany.com/report/carrier-screening-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795